Michael Rossi's Insider Trades & SAST Disclosures
Michael Rossi's most recent trade in Five Point Holdings LLC - Ordinary Shares - Class A was a trade of 14,869 Class A common shares done . Disclosure was reported to the exchange on March 12, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Michael Rossi.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Five Point Holdings LLC - ... | Michael E. Rossi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2025 | 14,869 | 14,869 (0%) | 0% | 0 | Class A common shares | |
| Y-Mabs Therapeutics Inc | Michael Rossi | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 5.20 per share. | 07 Mar 2025 | 3,917 | 137,083 (0%) | 0% | 5.2 | 20,368 | Common Stock |
| Y-Mabs Therapeutics Inc | Michael Rossi | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 210,700 | 210,700 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Michael Rossi | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 105,300 | 141,000 (0%) | 0% | 0 | Common Stock | |
| Five Point Holdings LLC - ... | Michael E. Rossi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2024 | 26,490 | 62,364 (0%) | 0% | 0 | Class A common shares | |
| Y-Mabs Therapeutics Inc | Michael Rossi | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 214,200 | 214,200 | - | - | Employee Stock Option (right to buy) | |
| Y-Mabs Therapeutics Inc | Rossi Michael | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 54,000 | 54,000 | - | - | Restricted Stock Units | |
| Y-Mabs Therapeutics Inc | Rossi Michael | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 35,700 | 35,700 (0%) | 0% | 0 | Common Stock | |
| Mirion Technologies Inc. -... | Michael Rossi | Medical Group President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.93 per share. | 01 Nov 2023 | 5,514 | 116,173 | - | 6.9 | 38,212 | Class A Common Stock |
| Mirion Technologies Inc. -... | Michael Rossi | Medical Group President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2023 | 41,242 | 121,687 | - | 0 | Class A Common Stock | |
| Five Point Holdings LLC - ... | Michael E. Rossi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 35,874 | 35,874 (0%) | 0% | 0 | Class A common shares | |
| Harvard Bioscience Inc. | Michael Rossi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.55 per share. | 29 Dec 2022 | 3,763 | 263,575 (0%) | 0% | 2.6 | 9,596 | Common Stock |
| Harvard Bioscience Inc. | Michael Rossi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.55 per share. | 29 Dec 2022 | 3,162 | 267,338 (0%) | 0% | 2.5 | 8,063 | Common Stock |
| Harvard Bioscience Inc. | Michael Rossi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.55 per share. | 29 Dec 2022 | 3,035 | 260,540 (0%) | 0% | 2.5 | 7,739 | Common Stock |
| Mirion Technologies Inc. -... | Michael Rossi | Medical Group President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 80,445 | 80,445 | - | 0 | Common Stock | |
| Harvard Bioscience Inc. | Michael Rossi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.63 per share. | 18 Jul 2022 | 7,008 | 270,500 (0%) | 0% | 3.6 | 25,439 | Common Stock |
| Harvard Bioscience Inc. | Michael Rossi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.95 per share. | 11 Jun 2022 | 6,325 | 277,508 (0%) | 0% | 4.0 | 24,984 | Common Stock |
| Five Point Holdings LLC - ... | Michael E. Rossi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2022 | 12,882 | 12,882 (0%) | 0% | 0 | Class A common shares | |
| Harvard Bioscience Inc. | Michael Rossi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 31,021 | 255,117 (0%) | 0% | 0 | Common Stock | |
| Harvard Bioscience Inc. | Michael Rossi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 28,716 | 283,833 (0%) | 0% | 0 | Common Stock | |
| Harvard Bioscience Inc. | Michael Rossi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.57 per share. | 18 Jul 2021 | 6,966 | 231,022 (0%) | 0% | 7.6 | 52,733 | Common Stock |
| Harvard Bioscience Inc. | Michael Rossi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2021 | 21,546 | 244,160 (0%) | 0% | 0 | Common Stock | |
| Harvard Bioscience Inc. | Michael Rossi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.64 per share. | 11 Jun 2021 | 6,172 | 237,988 (0%) | 0% | 7.6 | 47,154 | Common Stock |
| Harvard Bioscience Inc. | Michael Rossi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 38,462 | 185,738 (0%) | 0% | 0 | Common Stock | |
| Harvard Bioscience Inc. | Michael Rossi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 36,876 | 222,614 (0%) | 0% | 0 | Common Stock | |
| Five Point Holdings LLC - ... | Michael E. Rossi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 12,638 | 25,159 (0%) | 0% | 0 | Class A common shares | |
| Harvard Bioscience Inc. | Michael Rossi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2020 | 23,877 | 157,814 (0%) | 0% | 0 | Common Stock | |
| Harvard Bioscience Inc. | Michael Rossi | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.42 per share. | 18 Jul 2020 | 6,794 | 151,020 (0%) | 0% | 3.4 | 23,235 | Common Stock |
| Harvard Bioscience Inc. | Michael Rossi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 92,896 | 92,896 | - | - | Stock option (right to buy) | |
| Harvard Bioscience Inc. | Michael Rossi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 43,092 | 90,845 (0%) | 0% | 0 | Common Stock | |
| Harvard Bioscience Inc. | Michael Rossi | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 43,092 | 133,937 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges